Sorrento Therapeutics Overview
Company Headquarter: California, US
Founded: 1989
Workforce: ~200
Company Working: Sorrento Therapeutics (Sorrento) is an antibody-centric, clinical stage biopharmaceutical company that develops new treatments for cancer, inflammation, and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar antibodies, as well as clinical CAR-T therapies targeting solid tumors. It has a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB), clinical stage CAR-T, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir).
Strategy
Sorrento is focused on discovering various therapeutic applications for its existing product pipeline. The company is also focused on identifying, selecting, discovering, and acquiring promising pharmaceutical product candidates and products.
